| Accession Number: | 0001209191-21-064771 |
| Date: | 2021-11-12 |
| Issuer: | AEGLEA BIOTHERAPEUTICS, INC. (AGLE) |
| Original Submission Date: |
SMITH HUNTER C
C/O AEGLEA BIOTHERAPEUTICS, INC.
805 LAS CIMAS PARKWAY, SUITE 100
AUSTIN, TX 78746
| Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
|---|
| Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DIRECTOR STOCK OPTION (RIGHT TO BUY) | 7.04 | 2021-11-12 | deemed execution date | A | 60,000 (a) | 2031-11-11 | common stock 60,000 | $7.04 | 60,000 | direct |
| ID | footnote |
|---|---|
| f1 | the stock option vests and becomes exercisable in 36 equal monthly installments beginning on december 12, 2021 until such time as the option is 100% vested, subject to the continuing service of the reporting person on each vesting date. |
